Preparing for Phase IIIIV Maternal Group B Streptococcus Vaccine Trials and Surveillance in Africa
Building Pregnancy Registries, Infant Infection Monitoring, and Vaccine Confidence
Led by Barcelona Institute for Global Health · Updated on 2026-05-20
18100
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Group B Streptococcus GBS is a leading cause of sepsis and bacterial meningitis in newborns during the first 90 days of life, contributing significantly to newborn deaths. Researchers are preparing for maternal GBS vaccine trials in Africa to improve infection prevention through better data collection, surveillance, and vaccine confidence. The PROTECT project supports sites in Kenya, Malawi, Mozambique, and Uganda to establish uniform pregnancy and infant health data, monitor GBS incidence, and understand factors affecting vaccine acceptance.
The study consists of three main parts creating pregnancy exposure registries using electronic health records to track pregnancy and infant outcomes conducting a prospective observational GBS surveillance study among infants under 90 days with confirmed GBS infection at sentinel sites and assessing vaccine confidence through surveys and interviews with pregnant women, healthcare workers, and community leaders. These activities aim to strengthen healthcare systems for future vaccine trials and rollout.
Participants include pregnant women and their infants up to hospital discharge for the registry infants under 90 days with confirmed GBS infection for surveillance and pregnant women, healthcare workers, and community stakeholders for vaccine confidence research. The study involves collecting and analyzing medical records, microbiological data, and survey responses over periods ranging from 12 months to two years. Researchers will monitor pregnancy and infant outcomes, GBS infection rates, and vaccine knowledge to prepare for vaccine safety monitoring and effective vaccine implementation.
CONDITIONS
Brief Title
Preparing for Maternal GBS Vaccine Trials in Africa
Research Team
A
Azucena Bardají
L
Lucy Walmsley
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Women and their infants attending antenatal, delivery, or postpartum services at study sites in Uganda, Malawi, Mozambique, and Kenya
Infants under 90 days old with laboratory-confirmed Group B Streptococcus infection admitted at participating health facilities
Infants whose parents or guardians provide written informed consent
Residents within the catchment area of the participating health facilities
Pregnant women aged 18 years and above in Uganda, Kenya, and Mozambique
Pregnant women aged 16 years and above in Malawi, considered emancipated minors
Pregnant women and stakeholders willing to provide written informed consent
You will not qualify if you...
Pregnant women who are visiting or non-residents in the research area
Pregnant women who are unwell and unable to give consent to participate in the study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance
Duration - Up to 2 years
Participants who undergo routine care are observed to determine background pregnancy and infancy outcomes from medical records and registry data, and to monitor microbiologically confirmed neonatal sepsis burden including Group B Streptococcus (GBS) infections in infants under 90 days old.
Observation during routine healthcare visits
Vaccine Confidence Assessment
Duration - Approximately 2 years and 6 months
Pregnant women, healthcare providers, community members, and other stakeholders participate in surveys and interviews to assess knowledge, attitudes, and practices regarding maternal vaccines and willingness to participate in vaccine trials.
Multiple visits depending on participation in surveys and interviews
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Study of Invasive Bacterial Diseases Caused by Pneumococcus, Meningococcus, and Hemophilus in Children and Adults
Preparing for Phase IIIIV Maternal Group B Streptococcus Vaccine Trials and Surveillance in Africa
Building Pregnancy Registries, Infant Infection Monitoring, and Vaccine Confidence
Real-World Study of Maternal RSVpreF Vaccination Impact on Infant RSV-Related Respiratory Illness in Brazil
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina.
Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches.
Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes.
Rehana A Salam, Jai K Das, Chesarahmia Dojo Soeandy...